Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nicox's NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meeting

11/10/2021 | 01:30am EST
Press Release
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meeting

November 10, 2021 - release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced a poster presentation highlighting responder analyses results from the Dolomites Phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021 Annual Meeting being held from November 12-15, 2021 in New Orleans, LA, U.S.

The presentation will be available on demand from November 12, 2021 on the AAO website via a link dedicated to e-posters.

Poster title: NCX-470 for IOP-lowering: Results of Responder Analyses from the Phase 2 Dolomites Trial (Number PO 217) – Primary author: Dr. Thomas R. Walters, MD

Nicox’s lead clinical development product candidate, NCX 470 is a novel nitric oxide-donating prostaglandin analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage

Bryan, Garnier & Co         Victor Floc’h        Paris, France
Cantor Fitzgerald        Louise Chen        New York, U.S.
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Damien Choplain        Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 which are available on Nicox’s website (www.nicox.com).
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99



  • EN_ Poster presentation NCX 470 DolomitesAAO 2021_F

Primary Logo

Source: NICOX

2021 GlobeNewswire, Inc., source Press Releases

All news about NICOX SA.
01/21Nicox Provides Fourth Quarter 2021 Business and Financial Highlights
01/06NICOX : Half-year liquidity contract statement for NICOX
01/05Nicox Secures European Patent For Allergic Conjunctivitis Treatment
01/05Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030
2021NICOX SA. : Monthly statement on outstanding equity shares and voting rights
2021Nicox Screens First Patient in China in Late-Stage Trial For Glaucoma Treatment
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
2021GLOBAL MARKETS LIVE : General Motors, JP Morgan, Pfizer, Novavax, Ford...
2021Nicox Appoints Novartis Executive as Chief Scientific Officer
More news
Sales 2021 5,80 M 6,54 M 6,54 M
Net income 2021 -22,9 M -25,9 M -25,9 M
Net cash 2021 19,0 M 21,5 M 21,5 M
P/E ratio 2021 -4,29x
Yield 2021 -
Capitalization 105 M 119 M 118 M
EV / Sales 2021 14,8x
EV / Sales 2022 6,48x
Nbr of Employees 36
Free-Float 89,1%
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 2,43 €
Average target price 11,50 €
Spread / Average Target 373%
EPS Revisions
Managers and Directors
Michele Garufi Chairman & Chief Executive Officer
Sandrine Gestin Vice President-Finance
JosÚ Boyer Head-Research & Development
Doug Hubatsch Chief Scientific Officer
Jean-Franšois LabbÚ Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-4.89%119
MERCK KGAA-16.30%93 458
KYOWA KIRIN CO. LTD.-5.87%13 922